Actualización en la prescripción de inhibidores de la bomba de protones. Qué hacer y qué no hacer

Ladera, G.M. Saiz; Labari, María Elena Pejenaute; Pascual, Julia Natividad García

doi:10.1016/j.semerg.2020.09.011

Cited by 3 publications

(2 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Even though there is not enough evidence to recommend specific strategies to mitigate the adverse effects of PPIs, the American Gastroenterological Association has published clinical recommendations for good practices in the use of PPIs that have been recognized and implemented in various parts of the world (Ladera et al, 2020;SNS, 2017;Bhatia et al, 2019, AGRJ, 2022. The updates bring 10 recommendations, including the actions to be taken regarding the possible effects of these drugs on the small intestine and the absorption of VB12.…”

Section: Harmony Of Knowledge Exploring Interdisciplinary Synergiesmentioning

confidence: 99%

Chronic use of proton pump inhibitors and vitamin B12 deficiency: Current evidence and recommendations

Calou

2024

Harmony of Knowledge: Exploring Interdisciplinary Synergie

View full text Add to dashboard Cite

Proton pump inhibitors (PPIs) are among the most widely used drugs in the world. Representing the first choice of treatment for various disorders that affect the digestive system, these drugs are also among the most sought after for self-medication, since they are over-the-counter. The massive and prolonged use of PPIs ended up bringing to light adverse reactions that were eventually serious and often avoidable if they were used rationally. One of the main concerns about the chronic use of these drugs concerns their potential to cause vitamin B12 deficiency in chronic users, with damage ranging from megaloblastic anemia to severe neuropsychiatric disorders. Numerous studies have already addressed the topic without reaching a consensus. Currently, several indications postively relate the use of PPIs with vitamin B12 deficiency, and many others show the absence of a significant relationship. In general, the evidence is considered weak, and the recommendation among prescribers is that no action regarding serum monitoring or routine VB12 supplementation is necessary in patients on chronic use of proton pump inhibitors.

show abstract

Section: Harmony Of Knowledge Exploring Interdisciplinary Synergiesmentioning

confidence: 99%

Chronic use of proton pump inhibitors and vitamin B12 deficiency: Current evidence and recommendations

Calou

2024

Harmony of Knowledge: Exploring Interdisciplinary Synergie

View full text Add to dashboard Cite

show abstract

“…En el último informe sobre la Prestación Farmacéutica en el Sistema Nacional de Salud, 2020-2021 publicado por el Ministerio de Sanidad en 2022 10 , se observa que los inhibidores de la bomba de protones (IBP) constituye el grupo farmacoterapéutico, según la clasificación Anatomical Therapeutic Chemical Classification System (ATC), más consumido en España (6,7%), seguido de los hipolipemiantes (6,0%), los ansiolíticos (5,4%) y los analgésicos (4,4%). La dosis diaria definida por mil habitantes y día (DHD) de omeprazol en España en 2022 fue de 103,83, lo que representa 77,34% del total de consumo del grupo de IBP 11 .…”

Section: Introductionunclassified